Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of California, San Diego
Dana-Farber Cancer Institute
I-Mab Biopharma US Limited
University of Colorado, Denver
Dana-Farber Cancer Institute
Tempus AI
University of Kentucky
The University of Texas Health Science Center at San Antonio
GERCOR - Multidisciplinary Oncology Cooperative Group
Icahn School of Medicine at Mount Sinai
University of California, San Diego
Regeneron Pharmaceuticals
Thomas Jefferson University
M.D. Anderson Cancer Center
Elevation Oncology
University of Pittsburgh
Dana-Farber Cancer Institute
City of Hope Medical Center
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
EpicentRx, Inc.
Novartis
University of Arizona
Merck Sharp & Dohme LLC
University of Cincinnati
Case Comprehensive Cancer Center
Kura Oncology, Inc.
UNC Lineberger Comprehensive Cancer Center
University of Wisconsin, Madison
University of Cincinnati
The University of Texas Health Science Center at San Antonio
Stanford University
Brooklyn ImmunoTherapeutics, LLC
MacroGenics
Radiation Therapy Oncology Group
Pfizer
Tosk, Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
University of Michigan Rogel Cancer Center
SynCore Biotechnology Co., Ltd.
University of Wisconsin, Madison
University of Chicago
Bristol-Myers Squibb
University of Iowa